Piramal Pharma reports Q4 FY25 consolidated net profit of Rs. 153.50 Cr

The company has posted net profit of Rs. 91.13 crores for the Financial Year ended March 31, 2025

Piramal Pharma Q3 FY25 revenue up 13%

CDMO business delivered high-teen revenue growth for 9MFY25 driven by continued traction in the on-patent commercial manufacturing and generic API business

Iconovo and Lonza to collaborate on formulation development of an intranasal biologic

Lonza to develop spray-dried formulations for an intranasally-delivered biologic for Iconovo at its Center of Excellence for bioavailability enhancement and inhaled delivery in Bend (US)

AstraZeneca Pharma Pharma India to launch Breztri Aerosphere in Jan 2025

Piramal Pharma Q1 FY25 net loss narrows

EBITDA grew by 31% YoY with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24

Lupin completes acquisition of two brands from Sanofi in Europe and Canada

The transaction aligns with Lupin's strategy to grow its global presence in Specialty areas

Lupin appoints Dr. Ranjana Pathak as Chief Quality Officer

AstraZeneca Pharma India receives permission from CDSCO to import new drug

The receipt of this permission paves way for the launch of BREZTRI AEROSPHERE in India

Lupin's Joint Airways Initiative surpasses 10,000 patients

Alkem rolls out patient awareness drive under its breathe initiative

Education on Inhalation Therapy & Conducting Nationwide Awareness Camps, Alkem Breathe Initiative Addresses the Alarming Increase in Respiratory Diseases in India